Cullinan Therapeutics, Inc. — Form 8-K Summary
Reporting date: October 1, 2026. The filing reports a regulatory and clinical-development update; it does not present quarterly or annual financial results.
Business context
Cullinan announced that it has initiated submission of an NDA to the FDA for zipalertinib combined with platinum-based chemotherapy in previously untreated, locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations. The submission is proceeding under the FDA’s Real-Time Oncology Review (RTOR) program, which allows clinical data to be submitted before the complete application.
Key financial information
The filing provides no revenue, profit, cash flow, margin, debt, or liquidity figures. Cullinan is eligible for a $30.0 million payment from Taiho upon U.S. approval of zipalertinib for previously platinum-treated EGFR exon 20 insertion NSCLC, and up to $100.0 million upon U.S. approval for first-line treatment. These payments are contingent on regulatory approval; the filing does not state that either has been earned or received.
Clinical and regulatory developments
- The NDA submission is based on Phase 3 REZILIENT3 results. The trial met its primary endpoint, showing a statistically significant and clinically meaningful improvement in median progression-free survival for zipalertinib plus chemotherapy versus chemotherapy alone.
- Cullinan expects to complete the NDA submission by year-end 2026.
- Zipalertinib has FDA Breakthrough Therapy designation for locally advanced or metastatic EGFR exon 20 insertion NSCLC after prior platinum-based chemotherapy.
- A separate NDA seeking accelerated approval for zipalertinib monotherapy in that previously treated population remains under FDA review, with a PDUFA target action date of February 27, 2027.
Outlook, risks, and items to verify
The stated submission timetable is an expectation, and the described NDA pathway and potential Taiho milestone payments depend on FDA review and approval. The filing does not report an FDA decision or provide a forecast of financial results.
- Verify completion and timing of the first-line combination NDA submission.
- Review the full REZILIENT3 data, including safety results and the magnitude of benefit.
- Track FDA actions on both the first-line combination application and the separate monotherapy NDA, including the February 27, 2027 target date.
- Confirm whether regulatory approvals trigger either Taiho payment and the applicable terms.